This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 May 5;139(18):2728-2730.

doi: 10.1182/blood.2022015912.

(SUMO)-wrestling with rituximab

Affiliations

PMID: 35511190
DOI: 10.1182/blood.2022015912

Free article

Editorial

(SUMO)-wrestling with rituximab

Mark S Cragg. Blood. 2022.

Free article

. 2022 May 5;139(18):2728-2730.

doi: 10.1182/blood.2022015912.

Author

Affiliation

¹ University of Southampton.

PMID: 35511190
DOI: 10.1182/blood.2022015912

No abstract available

PubMed Disclaimer

Comment on

The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation.
Nakamura A, Grossman S, Song K, Xega K, Zhang Y, Cvet D, Berger A, Shapiro G, Huszar D. Nakamura A, et al. Blood. 2022 May 5;139(18):2770-2781. doi: 10.1182/blood.2021014267. Blood. 2022. PMID: 35226739 Free PMC article.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

24721/CRUK_/Cancer Research UK/United Kingdom

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems